R237
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 25
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.500
- ALLOGRAFT_REJECTION+0.460
- INTERFERON_GAMMA_RESPONSE+0.450
- INFLAMMATORY_RESPONSE+0.310
- COMPLEMENT+0.290
- E2F_TARGETS+0.270
- IL2_STAT5_SIGNALING+0.260
- IL6_JAK_STAT3_SIGNALING+0.260
- APOPTOSIS+0.250
- MITOTIC_SPINDLE+0.240
Top 10 suppressed
- PROTEIN_SECRETION-0.370
- TGF_BETA_SIGNALING-0.350
- ANDROGEN_RESPONSE-0.220
- ANGIOGENESIS-0.220
- UV_RESPONSE_DN-0.170
- KRAS_SIGNALING_DN-0.110
- APICAL_SURFACE-0.100
- UNFOLDED_PROTEIN_RESPONSE-0.100
- GLYCOLYSIS-0.090
- ESTROGEN_RESPONSE_LATE-0.080
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-C8-A12V-01A-11R-A115-07 | — | D | 0.772 |
| 2 | TCGA-E9-A3QA-01A-61R-A22K-07 | — | D | 0.764 |
| 3 | TCGA-PL-A8LZ-01A-31R-A36F-07 | — | D | 0.762 |
| 4 | 20030081.TNBC | — | D | 0.756 |
| 5 | TCGA-BH-A18V-06A-11R-A213-07 | — | D | 0.747 |
| 6 | TCGA-A2-A04Q-01A-21R-A034-07 | — | D | 0.744 |
| 7 | 20050099.TNBC | — | D | 0.742 |
| 8 | SRR5088821 | — | — | 0.732 |
| 9 | TCGA-OL-A66I-01A-21R-A29R-07 | — | D | 0.731 |
| 10 | 20080305.TNBC | — | D | 0.731 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 32 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.500 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.460 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.450 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.310 | Idelalisib | — uncovered |
| COMPLEMENT | 0.290 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.270 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.260 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.260 | Inavolisib | — uncovered |
| APOPTOSIS | 0.250 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.240 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.230 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.230 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.210 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.190 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.190 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.160 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.130 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.130 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.120 | Inavolisib | — uncovered |
| MYOGENESIS | 0.100 | Inavolisib | — uncovered |